**Supplemental Table: Baseline Characteristics of Participants Evaluable for Primary Endpoint**

|  |  |  |
| --- | --- | --- |
|  | **Vitamin D**  (n=73) | **Placebo**  (n=64) |
| Median age, years (range) | 44.1 (27-49) | 45.0 (25-50) |
| Race, N (%)  White  Black  Asian  Native American  Multi-Racial  Unknown | 62 (85)  5 (7)  3 (4)  1 (1)  2 (3)  0 | 58 (91)  2 (3)  2 (3)  0  0  2 (3) |
| Hispanic, N (%) | 6 (8) | 6 (9) |
| Median body mass index, kg/m2 (range) | 24.9 (18.8-42.6) | 26.1 (19.8-44.9) |
| Breast cancer risk status, N (%)\*  5-year breast cancer risk ≥1.67%  Lifetime breast cancer risk ≥20%  Atypical hyperplasia/LCIS  Prior stage 0-II breast cancer  High mammographic density\*\* | 33 (45)  19 (26)  7 (10)  4 (5)  62 (85) | 29 (45)  17 (27)  12 (19)  2 (3)  53 (83) |
| Baseline serum 25(OH)D, N (%)  <20 ng/mL  20-32 ng/mL | 22 (30)  51 (70) | 21 (33)  43 (67) |
| Baseline mammographic density, N (%)  Scattered fibroglandular densities  Heterogeneously/extremely dense | 11 (15)  62 (85) | 11 (17)  53 (83) |

**Abbreviations**: 25-hydroxyvitamin D (25(OH)D), lobular carcinoma *in situ* (LCIS)

\*Some women met multiple high-risk criteria.

\*\*Baseline mammogram with heterogeneously or extremely dense breasts.

24-month mammogram n=62

24-month mammogram n=69

12-month mammogram n=69

-Analyzed for primary endpoint n=64

12-month blood n=65

12-month mammogram n=80

-Analyzed for primary endpoint n=73

12-month blood n=69

6-month blood n=75

6-month blood n=83

Placebo n=105

Evaluable for toxicity n=102

Baseline mammogram n=69

Baseline blood n=88

Vitamin D n=103

Evaluable for toxicity n=102

Baseline mammogram n=76

Baseline blood n=90